Sarcoidosis, sandostatin Sarcoïdose, sandostatine
Conditions
Interventions
Patients will receive 20 mg of sandostatin injection intramuscular IM every month for six months.
Sponsors
Erasmus Medical Center, Department of Internal Medicine.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age above 18 years with obtained written consent 2. Have biopsy-proven symptomatic, stable, chronic sarcoidosis for minimal three years. 3. Have a positive SRS 4. Involvement of skin, joint, lymph nodes or lung. Patients with pulmonary involvement have a diffusing capacity between 60 and 75 percent.
Exclusion criteria
Exclusion criteria: 1. Corticosteroid use up to three months prior of trial 2. Chronic renal failure defined as a GFR below 50% 3. Liver disease 4. Have an indication for intensifying immunosuppressive therapy; threatening organ damage 5. Have failed on earlier anti TNF-alfa therapy 6. Have an underlying cardiac disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main endpoint is the change in uptake on somatostatin receptor scan. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is the composite clinical score using the following parameters: blood test (ESR, CRP, full blood count, lysozyme, ACE, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, sIL-2R), quality of life (RAND-36) and when applicable lung function test (FVC, DLCO) and skin evaluation. | — |
Contacts
Public ContactP.L.A. Daele, van
Erasmus Medical Center Dept. Internal Medicine D-419
Outcome results
None listed